News & Events

Press Releases

January 26, 2022

Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures

January 5, 2022

Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

January 3, 2022

Kyverna Therapeutics Announces Exclusive Worldwide Licenses With National Institutes of Health for Autologous and Allogeneic Anti-CD19 CAR T Cellular Therapies to Treat Autoimmune Diseases

September 15, 2021

Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer

April 13, 2021

Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer

January 13, 2020

Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences

Media Inquiries

To learn more about Kyverna’s work developing cell therapies for inflammatory and autoimmune disease, please reach out to us at:

media@kyvernatx.com